Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  histone deacetylase inhibitor therapy, histone deacetylase targeted therapy
Results 1-25 of 77 for your search:
Start Over
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 0761-010, NCI-2012-02782, NCT01728805
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine with or without Vorinostat in Treating Younger Patients with Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 60
Trial IDs: S1203, NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, NCT01802333
Exemestane with or without Entinostat in Treating Postmenopausal Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Capecitabine and Vorinostat in Treating Patients With Advanced or Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0803003591, NCI-2012-00151, NCT00719875
Entinostat in Combination with Aldesleukin in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 145208, NCI-2012-02900, CDR0000662915, NCI 7870, NCT01043159, RPCI #23, 7870, NCT01038778
Vorinostat and Combination Chemotherapy with Rituximab in Treating Patients with HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-075, NCI-2011-02508, AMC #75, CDR0000683379, NCT01193842
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACY-100, NCI-2011-03019, NCT01323751
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: T2009-003, NCI-2012-00563, NCT01483690
Panobinostat and Everolimus in Treating Patients with Metastatic or Unresectable Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 146308, NCI-2009-01599, NCT01037257, NCT01582009
Lenalidomide and Romidepsin with or without Dexamethasone in Treating Patients with Recurrent or Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma, or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 1112009392, NCI-2015-00921, RM-PTCL-PI-0021, NCT01742793
Romidepsin and Lenalidomide in Treating Patients with Relapsed or Refractory Lymphoma or Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-170, NCI-2013-00005, NCT01755975
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
Romidepsin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 13P.387, NCI-2013-01695, 080-38270-J94401, 13C.387, 2013-35, NCT01938833
Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-102, NCI-2014-00978, NCT01997840
Azacitidine and Romidepsin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAM3752, NCI-2014-00121, NCT01998035
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 0103-014, NCI-2013-02087, NCT02018926
HDAC6 Inhibitor ACY-1215 in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM4054, NCI-2014-01521, IRB-AAAM4054, NCT02091063
Carfilzomib, Romidepsin, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell and T-cell Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-179, NCI-2015-00109, NCT02341014
Mocetinostat and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-232, NCI-2015-00780, NCT02429375
Temozolomide and Vorinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HEMAML0017, NCI-2012-00229, 22794, NCT01550224
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-027, NCI-2012-00860, CDR0000732297, MSKCC-12-027, 9111, NCT01587352
Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients with Recurrent or Progressive High-Grade Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-14816, NCI-2013-00705, CTC-11-011, NCT01817751
Valproic Acid in Shortening Indwelling Catheter Placement Time in Patients with Metastatic Breast Cancer and Pleural Effusion
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0930, NCI-2014-01196, NCT01900730
Start Over